Article Text

Download PDFPDF

2022-RA-420-ESGO Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC) – real world data of the german quality assurance project (QS Ovar of the AGO Study Group)
  1. Sven Mahner1,
  2. Andreas du Bois2,
  3. Jacobus Pfisterer3,
  4. Felix Hilpert4,
  5. Markus Kerkmann5,
  6. Jalid Sehouli6,
  7. Nikolaus de Gregorio7,
  8. Lars Ch Hanker8,
  9. Florian Heitz2,
  10. Frederik Marmé9,
  11. Linn Lena Wölber10,4,
  12. Laura Holtmann5,
  13. Gabriele Elser11,
  14. Philipp Harter2 and
  15. AGO Study Group
  1. 1Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
  2. 2Klinik für Gynäkologie and Gyn. Onkologie, Ev. Kliniken Essen-Mitte, Essen, Germany
  3. 3Zentrum für Gynäkologische Onkologie, Kiel, Germany
  4. 4Onkologisches Therapiezentrum Krankenhaus Jerusalem, Hamburg, Germany
  5. 5MMF Research GmbH, Münster, Germany
  6. 6Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Universitätsmedizin Berlin, Charité, Berlin, Germany
  7. 7Frauenklinik, Klinikum am Gesundbrunnen, SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany
  8. 8Universitätsklinikum Schleswig-Holstein, Klinik für Gynäkologie und Geburtshilfe, Campus Lübeck, Lübeck, Germany
  9. 9Universitätsfrauenklinik, Mannheim, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany
  10. 10Department of Gynecology; University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  11. 11AGO Study Group, Wiesbaden, Germany


Introduction/Background Outcome of patients with AOC depends largely on treatment quality and expertise of treating physicians and centers. To assess treatment reality and quality in Germany, we initiated a nationwide quality assurance program.

Methodology All German hospitals treating patients with AOC were asked to document their patients with primary diagnosis in the third quarters of 2012 and 2016 in a central database. The current analysis focuses on patients with high-grade AOC stage III/IV.

Results In total, 1010 patients with high-grade AOC were documented. This represents 63% of all patients diagnosed in Germany. Median age was 65 years. The majority (774/1010 – 76.6%) were diagnosed with stage III disease and 947/1010 (93.8%) had serous, 34 (3.4%) endometrioid and 29 (2.9%) clear cell histology. 915/1010 (90.6%) had primary debulking surgery (PDS). Complete resection was achieved in 434/915 (47.4%) at PDS and in 54/95 (56.8%) at interval debulking surgery (IDS). Median PFS and OS in patients with PDS and complete resection was 29.7 and 63.1 months compared to 16.8 and 30.7 months in patients with residual disease (PFS: HR 0.46, 95% CI 0.37–0.54 and OS: HR 0.37, 95% CI 0.31–0.45). First-line chemotherapy was carboplatin/paclitaxel (TC) in 919/1010 (91%) of the patients, 627 (62%) also received bevacizumab (TCB) and 544 of these (87%) also received bevacizumab maintenance therapy. Median PFS and OS with TCB was 23.3 and 46.2 months and 18.5 and 39.0 months with TC (PFS: HR 0.86, 95% CI 0.73–1.01 and OS: HR 0.79, 95% CI 0.66–0.95).

The rate of complete tumor resection at surgery as well as the use of bevacizumab increased between the two periods.

Conclusion The majority of patients were treated with primary surgery followed by TCB. Outcome was best when complete tumor resection was achieved at primary surgery and patients received combination chemotherapy with maintenance treatment.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.